Katherine Neville

About the Author

Katherine Neville

Katherine Neville, Ph.D. is a partner at Marshall, Gerstein and Borun LLP. Her practice focuses on biotechnology patent prosecution for a range of companies, from large pharma to start-ups and universities. For over a decade she has assisted clients with strategic portfolio management in the US and foreign jurisdictions, as well as patent preparation and prosecution, freedom to operate and patentability opinions, and due diligence. She can be reached at 312-474-6633 or at kneville@marshallip.com.

IP: Supreme Court hears oral argument on whether isolated DNA is a product of nature

By Katherine Neville | May 7, 2013

On April 15, the Supreme Court heard oral argument in the highly anticipated Association for Molecular Pathology v. Myriad Genetics case.
IP: Business methods, diagnostics and abstract ideas

By Katherine Neville | April 23, 2013

The Supreme Court has taken an increased interest in patent cases in recent years. Two cases important to entities that file business method patents, software patents and medical diagnostics are Bilski v. Kappos and Mayo Collaborative Services v. Prometheus Laboratories, Inc.
IP: Federal Circuit goes all in on double patenting

By Katherine Neville | March 26, 2013

In the Federal Circuit’s recent 2-1 decision In re Hubbell, the court clarified the scope of the doctrine of obviousness-type double patenting as it applies to applications and patents that have overlapping inventors, but are not commonly owned.
IP: The Notebook, end of a love story?

By Katherine Neville | February 26, 2013

It has always been important to keep thorough records of conception and reduction to practice of an invention in case of an interference between two patents or to antedate a prior art reference, usually accomplished by signing and witnessing laboratory notebooks.